Loading
Cerebrovascular and Carotid Artery Diseases / Cancer, Lipids, and Metabolism · Journal article
Кардиология В Беларуси · September 9, 2026
A consensus or society position rather than new primary data.
This is a narrative review examining common clinical misconceptions about statin therapy and fixed-dose rosuvastatin–ezetimibe combinations in high-risk patients. The article compares misconceptions with research evidence but does not report new efficacy or safety data, and the abstract provides no specific findings or quantitative results.
Narrative review / Expert commentary. High- and very-high-risk patients with atherosclerotic cardiovascular disease. Intervention: Fixed-dose combination of rosuvastatin and ezetimibe; statin therapy. Republic of Belarus and worldwide.
Many high- and very-high-risk patients do not receive adequate lipid-lowering therapy and fail to achieve targeted lipid values despite availability of effective combination therapies. Review addresses common misconceptions among patients and physicians regarding statin adverse effects, treatment adherence, and specific treatment characteristics. Article examines associations between statin use and cancer, liver disease, dementia, diabetes risk, and cataracts across different patient categories.
Abstract does not report specific efficacy metrics, effect sizes, or safety outcomes. Review addresses common misconceptions among patients and physicians regarding statin adverse effects, treatment adherence, and specific treatment characteristics.
This article provides expert synthesis on statin myths and evidence to support informed clinical decision-making about combination lipid-lowering therapy and address patient adherence barriers. Clinicians should refer to this for clarity on statin safety across specific adverse event concerns.
This is a narrative review addressing clinical misconceptions about statin therapy and fixed-dose rosuvastatin–ezetimibe combinations, synthesizing existing evidence rather than reporting new empirical data.
As stated by the source record.
This article provides expert synthesis on statin myths and evidence to support informed clinical decision-making about combination lipid-lowering therapy and address patient adherence barriers. Clinicians should refer to this for clarity on statin safety across specific adverse event concerns.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Сердечно-сосудистые заболевания атеросклеротического генеза – основная причина смертности в Республике Беларусь и во всем мире. Несмотря на наличие высокоэффективных и безопасных комбинированных лекарственных средств, многие пациенты высокого и очень высокого риска не получают адекватную гиполипидемическую терапию и не достигают целевых показателей липидограммы. Статья посвящена самым распространенным среди пациентов и врачей заблуждениям, касающимся приема статинов, их побочным эффектам, особенностям приема и их влиянию на приверженность терапии. Сопоставляются имеющиеся заблуждения и данные исследований. Освещаются новые данные, касающиеся использования статинов у разных категорий пациентов, связь их приема с онкопатологией, заболеваниями печени, деменцией и риском развития сахарного диабета и катаракты. Atherosclerotic cardiovascular disease is the leading cause of death in the Republic of Belarus and worldwide. Despite the availability of highly effective and safe combination therapies, many high- and very-high-risk patients do not receive adequate lipid-lowering therapy and fail to achieve their targeted lipid values. The article addresses the most common misconceptions among patients and physicians regarding statin therapy, their adverse effects, specific treatment options, and their impact on treatment adherence. Existing misconceptions are compared with research findings. New data regarding statin use in various patient categories are highlighted, as well as their association with cancer, liver disease, dementia, and the risk of diabetes and cataracts while taking statins.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.